News
Biosimilars. The University of Cadiz and Curaxys have signed a Long Term
Framework Research and Development Agreement for the Biosimilars Research
By
Curaxys - 29
November 2009
A multidisciplinary team of researches
specialized on Biotechnology, Biomedicine, Science and Environmental
sciences, will research in new processes for the biosimilars production.
(1888PressRelease)
November 29, 2009
- Researches of the UCA will collaborate with the biopharmaceutical company
Curaxys to develop therapeutic proteins for cancer treatment.
The Chancellor of the University, Dr. Diego Sales and Dr. Manuel Esteban
Chief Executive Officer of Curaxys have signed a Framework Research
Agreement (FRA). The sign ceremony was attended by General Manager of Bahia
Competitiva (BC); Antonio Perales, the Vice-chancellor of Research and
Development activities: Dr Francisco Antonio Macias and the General Manager
of UCA: Dr. José Manuel Gomez.
Curaxys is a biopharmaceutical company located on the Technological Park
Tecnobahia devoted to the research, development, production and
commercialization of medicines and services in the biopharmaceuticals field.
A multidisciplinary team from the UCA will be researching in four
biotechnological lines and molecular biology, on mammalian cell, virus,
insect cell and bacteria involving four research groups of the Faculties of
Health Science, Marine Science among others.
The Chancellor explained that this initiative is supported by the Plan de
Accion de Bahia Competitive (BC). The target is to encourage the development
of high technology industries into the Cadiz Bay Area.
The Chancellor said that the initiatives of research activities will be
carried out in the Cathedra Curaxys and complemented with training
activities, those are “according to our policy because in two years time we
wanted to be ready the new University Degree on Biotechnology”
Curaxys is a company that will be the starting point “for a strategic
business and the future of Cadiz´s Bay” Mr. Perales remarked and said that
the Andalucia Autonomous Government is deciding to collaborate with Curaxys,
through the Innovation, Science, Enterprise and Health Authorities Councils.
The Chancellor and the General Manager of BC mentioned the excellent
background of the promoter, Dr. Manuel Esteban, Chemist and Doctor in
Pharmacology, which was defined as a researcher in the front line of the
biopharmacy with a proven background in the international pharmaceutical
field.
Dr. Esteban thanks the UCA`s support, because the agreement “has been
possible due to a excellent research infrastructures and humans resources
available for Curaxys”. Dr. Esteban said that Curaxys should be a seeding
company for futur start up high-tech companies on biotechnology and pharmacy
according to the “relevant rule of Andalucia into the Spanish pharmaceutical
consumption, being is the first pharmaceutical market of Spain and
unbalanced with the reduced number of pharmaceuticals companies located on
the Region”.
Latter, the vice-chancellor, Dr. Macias mentioned that despite to the
project has been created by a gaditaniam in his town; the project has a
remarkable international projection and market.
*Biosimilars Definition: Biosimilars or Follow-on biologics are terms used
to describe officially approved new versions of innovator biopharmaceutical
products: as recombinant proteins, monoclonal antibodies, etc.